TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
Prof. Kieron Dunleavy

Kieron Dunleavy

Scientific Advisory Board Member

Professor Kieron Dunleavy is a Professor of Medicine, Director of the Lymphoma Program and Co-Director of the Microbial Oncology Program in the Division of Hematology & Oncology at The George Washington University Cancer Center, Washington D.C., US. Prof. Dunleavy was educated at University College Dublin, Dublin, IE, and subsequently at the National Cancer Institute (NCI), Bethesda, US. Following his fellowship at the NCI, he remained on staff as an attending physician and has been the Clinical Director of the Lymphoid Malignancies Branch at the NCI. Prof. Dunleavy’s work to date has focused on the biology and treatment of lymphoid diseases. His interests include aggressive and indolent lymphomas, as well as virus-associated and microbe-associated lymphoid diseases, such as those associated with EBV and HIV. He serves on the scientific advisory board of the Lymphoma Research Foundation and on the editorial board of several journals, including HaematologicaBlood, and Leukemia & Lymphoma. Prof. Dunleavy has published over 100 manuscripts and textbook chapters and frequently presents his work nationally and internationally.

Filter by content: